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Abstract
Background:  Phosphorylation is a reversible post-translational modification that affects the
intrinsic properties of proteins, such as structure and function. Non-synonymous single nucleotide
polymorphisms (nsSNPs) result in the substitution of the encoded amino acids and thus are likely
to alter the phosphorylation motifs in the proteins.
Methods: In this study, we used the web-based NetPhos tool to predict candidate nsSNPs that
either introduce or remove putative phosphorylation sites in proteins that act in DNA repair and
cell cycle pathways.
Results: Our results demonstrated that a total of 15 nsSNPs (16.9%) were likely to alter the
putative phosphorylation patterns of 14 proteins. Three of these SNPs (CDKN1A-S31R, OGG1-
S326C, and XRCC3-T241M) have already found to be associated with altered cancer risk. We
believe that this set of nsSNPs constitutes an excellent resource for further molecular and genetic
analyses.
Conclusion: The novel systematic approach used in this study will accelerate the understanding
of how naturally occurring human SNPs may alter protein function through the modification of
phosphorylation mechanisms and contribute to disease susceptibility.
Background
Phosphorylation is a common, reversible post-transla-
tional modification that occurs at serine (S), threonine
(T), and tyrosine (Y) residues in proteins [1]. Overall,
phosphorylation can alter the structure, function, interac-
tion, stability, and the sub-cellular location of the proteins
[2-4], and therefore play an indispensable role in regula-
tion of the cellular processes such as signal transduction,
gene expression, cytoskeletal regulation, apoptosis, home-
ostasis, cell cycle, and DNA damage recognition and
repair [5-11]. The phosphorylation state of a protein is
determined by the opposing actions of kinases and phos-
phatases [12]. Proteins may contain multiple phosphor-
ylation sites, which may be targeted by different kinases/
phosphatases [2]. The activity of kinases and phos-
phatases at different times and/or upon different stimuli
provides a means of powerful control over the protein
phosphorylation state and thus the biological processes
the protein is involved in.
In the post-genomic era, there is an expanding interest in
identification of the single nucleotide polymorphisms
Published: 19 August 2005
BMC Cancer 2005, 5:107 doi:10.1186/1471-2407-5-107
Received: 24 November 2004
Accepted: 19 August 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/107
© 2005 Savas and Ozcelik; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:107 http://www.biomedcentral.com/1471-2407/5/107
Page 2 of 6
(page number not for citation purposes)
(SNPs) that might affect the protein function and thus
contribute to the disease susceptibility. The non-synony-
mous SNPs (nsSNPs) substitute encoded amino acids in
proteins, and therefore are good candidates as disease-
modifiers. A variety of approaches have been developed
and applied, based on criteria such as the evolutionary
conservation status or structural parameters, to character-
ize and select the nsSNPs that are most likely to have func-
tional consequences [13-19].
In this report, we predicted the potential effect of a set of
nsSNPs [20,21] in altering the phosphorylation status of
DNA repair and cell cycle proteins using the NetPhos tool
[22], which is an artificial neural network method that
predicts the phosphorylation sites with a sensitivity of 69–
96%. DNA repair and cell cycle pathways interact during
the cell growth and division to maintain the genomic sta-
bility of dividing cells. Abnormalities in the DNA repair
and/or the cell cycle pathways can lead to abnormal cell
growth/division or cellular death [23], and are implicated
in many human diseases, including cancer [24-30]. Func-
tional significance of many phosphorylated residues of
several DNA repair and cell cycle proteins has already
been evaluated. For example, phosphorylation of STATα
residue S727 is required for its maximal transcriptional
activation [31] and enhances its binding to the BRCA1
protein [32]. Similarly, phosphorylation of S383 and
S387 are required for the FANCG function during mitosis
[33]. Likewise, mutations of the phosphorylated residues
Ser366 and Thr387 of p53 affect its transactivation func-
tion [34]. To our knowledge, although SNPs of DNA
repair and cell cycle proteins have already been shown to
contribute to cancer risk [35-37], the potential role of nsS-
NPs in alteration of phosphorylation patterns of proteins
has not been evaluated before. Therefore, the novel
approach described in this study will accelerate the forma-
tion of a bridge between variations in DNA repair/cell
cycle function and predisposition to disease.
Methods
The nsSNPs extracted from public SNP databases were
previously reported [20,21], however, only the nsSNPs
that were found in ≥2 chromosomes in a sample panel of
≥46 chromosomes were included into that manuscript. A
total of 89 nsSNPs from 47 genes involved in DNA repair
and cell cycle constituted the final data set. The NetPhos
[22] algorithm was utilized to predict putative phosphor-
ylation sites for both the wild type and the variant protein
sequences. Only the predictions that remove or create a
site at either the SNP location or at kinase recognition
motifs are included into this manuscript. Please note that
the BRCA1 and NFKB1 proteins were initially identified as
cell cycle protein interacting proteins [21]. However, in
this manuscript, we classified the BRCA1 as a DNA repair
and the NFKB1 as a cell cycle protein. The mouse ortho-
logues were retrieved from the LocusLink resource of
NCBI [38] and aligned with the human proteins using the
ClustalW program [39] to identify the corresponding
mouse residue.
Results and discussion
We utilized the NetPhos algorithm to predict putative
phosphorylation sites along the DNA repair and cell cycle
proteins, and studied whether 89 naturally occurring nsS-
NPs (64 from 28 DNA repair and 25 from 19 cell cycle
genes) might alter the phosphorylation patterns in these
proteins. The sensitivity of NetPhos prediction has been
reported to be 69–96% with a false-positive prediction
rate of 0–26% for Y, 0–11% for S, and 0–14% for T [22].
The results obtained using the NetPhos software are
shown in Table I, and are summarized in Table II. Our
results have shown that 16.9% (15/89) of the nsSNPs
studied are likely to abolish or create 17 putative phos-
phorylation sites in 44.0% (14/32) of the proteins. As
summarized in Table II, five nsSNPs (ERCC5-S311C,
OGG1-S326C, XRCC3-T241M, CCND3-S259A, and
CDKN1A-S31R) were predicted to abolish putative phos-
phorylation sites, whereas four nsSNPs were predicted to
create putative phosphorylation sites in the proteins
(ERCC2-H201Y, ERCC4-P379S, LIG4-P231S, and
XRCC1-P309S). These nsSNPs resulted in the addition or
removal of a S, T or Y residue at the predicted phosphor-
ylation site.
The kinase recognition/interaction motif involves 7–12
amino acids around the phosphorylated residue [40], and
the physicochemical characteristics of these amino acids
determine the specificity of the protein kinases [41,42].
Thus, the amino acid substitutions within the kinase rec-
ognition motifs are likely to influence the substrate recog-
nition and the subsequent phosphorylation by kinases.
Accordingly, we have identified six nsSNPs (Table I, II)
located within the phosphorylation motif of six proteins
(within 4 amino acids on either side of the putative phos-
phorylated residue based on NetPhos outputs) that abol-
ished eight putative phosphorylation sites (BRCA1-P871L
at S868, BRCA1-S1040N at S1041, ERCC5-S311C at S310,
IGHMBP2-T671A at S672, WRN-S1079L at S1083 and at
S1084, CCNI-V207I at S208, and NFKB1-H712Q at
T716). Interestingly, NetPhos predicts two overlapping
phosphorylation motifs for the ERCC5-S311C nsSNP
(S311 SLPSSSKMH and S310 ESLPSSSKM), which are
both completely abolished by the substitution of the ser-
ine residue (position 311) with a cysteine (Table I). Simi-
larly, the WRN-S1079L nsSNP was also predicted to
remove 2 putative overlapping phosphorylation motifs
(S1083 SKTVSSGTK and S1084 KTVSSGTKE)
simultaneously.BMC Cancer 2005, 5:107 http://www.biomedcentral.com/1471-2407/5/107
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The Swiss-Prot [43], HPRD [44], PhosphoBase [45], and
Phospho.ELM [46] databases and the existing literature
did not reveal any experimentally verified phosphoryla-
tion at the predicted sites. Analysis of the mouse ortho-
logues showed that the corresponding amino acids at the
BRCA1-S1041, CCNI-S208, ERCC5-S310, IGHMBP2-
S672, WRN-S1083 and XRCC3-T241 residues were also
predicted to be phosphorylated, suggesting that these
motifs/sites might have been evolutionarily conserved
between two species. On the other hand, the remaining
phosphorylation sites, which are not detected in mouse
proteins, may represent the newly evolved phosphoryla-
tion motifs in human. However, considering the false-
positive rate of NetPhos as well as the possibility that the
negative selection acting on the nsSNP sites can result in
higher false-positive rates, we cannot totally rule out that
all predictions in Table 2 are false. Yet these predictions
are still of a great value and suggest possible phosphoryla-
tion sites that can be experimentally evaluated. In future,
when sufficient molecular data regarding the phosphor-
ylation status of orthologous proteins is available, more
systematic analyses can be performed to maximize the
accuracy of phosphorylation predictions.
We have also performed an extensive literature review to
investigate the role of the reported nsSNPs (minor allele
Table 1: nsSNPs that abolish or create putative phosphorylated residues in DNA repair and cell cycle proteins. Only the NetPhos [22] 
predictions that remove or create a site at either the SNP location or at kinase recognition motifs are shown. The nsSNPs that create 
or abolish putative phosphorylation sites at the nsSNP position are shown in bold. Under the wild type and variant columns are the 
NetPhos outputs with the location of the amino acid, the phosphorylation motif (the putative phosphorylated residue is underlined), 
the score, and the residue being phosphorylated. 1 and 2 under the frequency column represents the nsSNP minor allele frequencies 
<5% and ≥5%, respectively [20-21]. Please note that the BRCA1 and NFKB1 proteins were initially identified as cell cycle protein 
interacting proteins [21]. However, in this manuscript, we classified the BRCA1 as a DNA repair and the NFKB1 as a cell cycle protein. 
§The putative phosphorylation sites that are also predicted in mouse proteins.
Pathway Gene Accession # SNP ID nsSNP Freq. Wild Type Variant
DNA repair BRCA1 NM_007294.1 SNP000007492
rs799917
P871L 2 868 SKRQSFAPF 0.599 *S* -
BRCA1 NM_007294.1 rs4986852 S1040N 1 §1041 KEASSSNIN 0.557 *S* -
ERCC2 NM_000400.1 SNP000000054
rs1799792
H201Y 1 - 201 YSILYANVV 0.745 *Y*
ERCC4 NM_005236.1 SNP000000067 P379S 1 and 2 - 379 LESNSKWEA 0.507 *S*
ERCC5 NM_000123.1 SNP001026027
rs2307491
S311C 1 a) 311 SLPSSSKMH 0.990 *S*
b) §310 ESLPSSSKM 0.645 *S*
-
IGHMBP2 NM_002180.1 SNP000012785
rs622082
T671A 2 §672 GPATSTRTG 0.634 *S* -
LIG4 NM_002312.2 rs3093765 P231S 1 - 231 QLHDSSVGL 0.562 *S*
OGG1 NM_002542.4 SNP000064679 S326C 2 326 DLRQSRHAQ 0.990 *S* -
WRN NM_000553.2 SNP001026663
rs3087414
S1079L 1 a) §1083 SKTVSSGTK 0.790 *S*
b) 1084 KTVSSGTKE 0.829 *S*
-
XRCC1 NM_006297.1 SNP000064196
rs25491
P309S 1 - 309 EPRRSRAGP 0.996 *S*
XRCC3 NM_005432.2 SNP000000060 T241M 2 §241 SLGATLREL 0.849 *T* -
Cell Cycle CCND3 NM_001760.2 rs1051130 S259A 2 259 LREASQTSS 0.982 *S* -
CCNI NM_006835.2 rs4252903 V207I 1 §208 LAMVSLEME 0.664 *S* -
CDKN1A NM_000389.2 SNP000003435
rs1801270
GAI870831
GAI1503061
S31R 2 31 SEQLSRDCD 0.924 *S* -
NFKB1 NM_003998.2 rs4648099 H712Q 1 716 HVDSTTYDG 0.595 *T* -
Table 2: Distribution of the nsSNPs predicted to alter the phosphorylation sites.
nsSNP DNA repair Cell cycle Total
Abolished ≥1 putative phosphorylated residue (S, T or Y) at the nsSNP location 3 2 5
Abolished ≥1 putative phosphorylated residue by changing the kinase recognition motif 5 2 7
Created ≥1 putative phosphorylated residue (S, T or Y) at the nsSNP location 4 0 4
Created ≥1 putative phosphorylated residue by changing the kinase recognition motif 0 0 0BMC Cancer 2005, 5:107 http://www.biomedcentral.com/1471-2407/5/107
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frequencies ≥5%) in human cancer predisposition (Table
III). Supporting our hypothesis, three SNPs (CDKN1A-
S31R, OGG1-S326C, and XRCC3-T241M) have already
found to be associated with altered cancer risk. XRCC3-
T241M nsSNP was reported to be associated with
increased breast cancer [47,48] and melanoma risk [49],
and was also found to be protective against bladder cancer
in heavy smokers [50]. XRCC3 is a key DNA repair protein
involved in base excision repair [29] and is involved in
repairing the alterations caused by many DNA damaging
agents. Recently, the XRCC3-M241 variant has been asso-
ciated with increased risk of incidence of tetraploid cells,
frequently observed in cancers, through affecting the func-
tion of the XRCC3- and Rad52-associated RPA protein
[51]. Similarly, the OGG1-S326C SNP was found to be
associated with increased lung [52], orolaryngeal and
esophageal cancer risk [53,54]. OGG1 is a DNA repair
protein that is protective against the mutations induced
by the 8-hydroxyguanine. Yamane et al., [55] suggested
that OGG1-C326, when compared to OGG1-S326, was
associated with a lower repair capacity for 8-hydroxygua-
nine induced mutations in human cells. In the case of
CDKN1A-S31R, the CDKN1A-S31 was suggested to be
associated with increased endometrial cancer [56]
whereas CDKN1A-R31 was associated with increased pri-
mary open-angle glaucoma [57] and esophageal cancer
risk [58]. The CDKN1A-R31 form of the protein was not
significantly different than the CDKN1A-S31 form in
terms of its ability to suppress colony formation [59].
However, it is not clear whether this result would suggest
that the CDKN1A-R31 would be functionally equivalent
to the wild type allele in other diverse cellular mecha-
nisms that the CDKN1A protein is involved in, such as
apoptosis, cell migration, and senescence [60,61].
In addition to the SNPs already implicated in cancer risk,
we identified one relatively common nsSNP potentially
altering the phosphorylation pattern of a major breast and
ovarian cancer susceptibility gene, BRCA1. The BRCA1-
P871L SNP was not found to be associated with either
breast [62] or ovarian cancer risk [63], however, further
analyses is required to see whether this nsSNP or the other
nsSNPs in Table III play a role in susceptibility to other
cancer types.
How can we explain that commonly occurring nsSNPs
(minor allele frequencies ≥5%) are likely to affect the
phosphorylation and thus the function of the proteins? If
the phosphorylation site is necessary for the function of
the protein and the protein is necessary for the fitness of
the organism (indispensable/essential protein), then we
would expect such nsSNPs (deleterious alleles) to be
either removed from the population or be kept at low
allele frequency by means of the purifying selection. Thus,
in this case, one can conclude that the common nsSNPs
presented in this report can be falsely predicted as remov-
ing/creating putative phosphorylation sites by NetPhos
program. However, the allele frequencies of the deleteri-
ous alleles from proteins that are essential for fitness get
higher than expected when the nsSNPs are a) created by
hot-spot mutation mechanism(s), b) subject to balancing
selection, too [64]. Alternatively, even though the nsSNPs
(and the abolished/created phosphorylation sites) have
important impact on the protein function, the protein
and/or the altered protein function may not affect the fit-
Table 3: Common nsSNPs with a possible role in cancer predisposition. Only the information derived from the studies on the protein 
function as well as the studies with a suggestion of disease-association have been included. 1 and 2 under the frequency column 
represents the nsSNP with minor allele frequencies <5% and ≥5%, respectively [20-21].
Pathway Gene nsSNP Possible effect on phosphorylation Frequency Functional analysis Cancer risk association
DNA repair BRCA1 P871L Abolishes at S869 2 - -
ERCC4 P379S Creates at S379 1 and 2 - -
IGHMBP2 T671A Abolishes at S672 2 - -
OGG1 S326C Abolishes at S326 2 Yamane et al. [55] Sugimura et al. [52];
Xing et al. [53];
Elahi et al. [54]
XRCC3 T241M Abolishes and T241 2 Yoshihara et al. [51] Winsey et al. [49];
Kuschel et al. [47];
Shen et al. [50];
Figueiredo et al. [48]
Cell cycle CCND3 S259A Abolishes at S359 2 - -
CDKN1A S31R Abolishes at S31 2 Chedid et al. [59] Wu et al. [58];
Roh et al. [56];
Tsai et al. [57]BMC Cancer 2005, 5:107 http://www.biomedcentral.com/1471-2407/5/107
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ness, which can also explain the lack of purifying selection
against such nsSNPs and their relatively high minor allele
frequencies. Besides, the biological consequences of
altered protein function may only be exerted under cer-
tain environmental conditions.
Conclusion
Here we report a set of nsSNPs in DNA repair and cell
cycle genes that are predicted to alter the phosphorylation
motifs of the encoded proteins, with possible conse-
quences on protein function, structure, interaction, and
stability. If the nsSNPs with a ≥5% minor allele frequency
listed in Table III do indeed alter the phosphorylation
state of the corresponding proteins, they then represent
important candidates for disease susceptibility studies,
especially relating to cancer risk. We conclude with the
suggestion that our approach and the resulting data indi-
cate a novel mechanism of SNP action: alteration of the
functional characteristics of the proteins through phos-
phorylation may significantly contribute to our under-
standing of the molecular basis of complex diseases, such
as cancer. This study is unique in the sense that it system-
atically links the possible post-translational modification
functional effects of SNPs to disease (cancer)
predisposition.
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